Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
3.
J Dtsch Dermatol Ges ; 5(8): 662-8, 2007 Aug.
Article in English, German | MEDLINE | ID: mdl-17659039

ABSTRACT

BACKGROUND: Primary cutaneous lymphomas form a heterogeneous group of lymphatic neoplasias. They manifest themselves on the skin and are the second most frequent group of non-Hodgkin lymphoma (NHL) following gastrointestinal lymphomas. The number of epidemiologic studies is small due to limited availability and limited comparability on population-based data. PATIENTS AND METHODS: In the present study the first evaluation of the German Central Registry for Cutaneous Lymphomas (ZRKL) of the German Society of Dermatology (DDG) is undertaken on the basis of 998 patients. The epidemiology of cutaneous lymphomas in Germany is compared to other national or regional lymphoma registries. RESULTS: Based on the registration of 998 patients from 26 clinics in Germany,a clear predominance of cutaneous T-cell lymphomas (85 %) in comparison to cutaneous B-cell lymphomas (14 %) is seen. The most frequent representative of CTCL is mycosis fungoides,composing 62 % of cases with a slight predominance of men (M:F = 1.6:1). Differences are also seen in stage of the disease at first presentation of patients with cutaneous lymphomas.While, for example, 80 % of patients with mycosis fungoides in Germany present in early stages (I-IIA),in the USA 34 % of patients are in the tumor stage or have organ involvement at presentation. CONCLUSIONS: The ZRKL of the DDG for the first time presents epidemiologic data from Germany, allowing comparison with other nations for the study of etio-logical factors and socioeconomic influences. Further, the ZRKL supports the development of uniform and quality-oriented diagnostic criteria and therapeutic options. Finally, the ZRKL provides a foundation for future intensive study of clinical and scientific questions regarding cutaneous T- and B-cell lymphomas.


Subject(s)
Lymphoma/epidemiology , Registries , Risk Assessment/methods , Skin Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , Dermatology/statistics & numerical data , Female , Germany/epidemiology , Humans , Male , Middle Aged , Prevalence , Risk Factors , Societies, Medical
4.
Eur J Dermatol ; 16(4): 391-3, 2006.
Article in English | MEDLINE | ID: mdl-16935796

ABSTRACT

Imiquimod as a topical immune response modifier leads to a localized production of interferon and other cytokines. Apart from its use for genital warts it has therefore been used as treatment for different cutaneous neoplasms, including a few cases of cutaneous T-cell lymphoma. We treated 8 patients (4 with mycosis fungoides, 1 with CD30+ anaplastic large cell lymphoma and 3 with primary cutaneous B-cell lymphoma) with topical imiquimod. Therapy was started three times per week, in cases without response, the frequency was increased to a daily application. Two patients with mycosis fungoides and the patient with the CD30+ anaplastic large cell lymphoma had a complete clinical remission, the other two patients with mycosis fungoides did not show a response to imiquimod. Of the patients with cutaneous B-cell lymphoma, two reached a partial remission, one did not respond to therapy. Two patients had side effects such as erythema and pruritus which disappeared when the frequency of therapy was reduced. Our preliminary data show that imiquimod might be effective in some cases with therapy resistant lesions of cutaneous T-cell lymphoma as well as of cutaneous B-cell lymphoma, but more controlled studies are needed.


Subject(s)
Aminoquinolines/administration & dosage , Antineoplastic Agents/administration & dosage , Lymphoma, B-Cell/drug therapy , Lymphoma, T-Cell, Cutaneous/drug therapy , Mycosis Fungoides/drug therapy , Skin Neoplasms/drug therapy , Administration, Topical , Adult , Aged , Female , Humans , Imiquimod , Male , Middle Aged
5.
J Dtsch Dermatol Ges ; 4(3): 198-204, 2006 Mar.
Article in German | MEDLINE | ID: mdl-16626316

ABSTRACT

Medical school graduates are required to deal with complex situations in their future work which require profound theoretical knowledge as well as many practical skills. The University of Hamburg used a new educational law (AappO 2002) as catalyst to define learning objectives relevant for practice and to guarantee a close connection between theory and practice. A newly founded curriculum committee with twelve members developed a strategy and structure for the new clinical curriculum (KliniCuM) in weekly sessions. The subject dermatology and venereology is taught in the thematic block "The Internal and External Human Being" in integrated courses with the subjects internal medicine, pathology and pharmacology. The teaching modules (introductory lectures, symptom-oriented lectures, problem-based tutorials and bedside-teaching) are practice oriented and teach diseases and skills of dermatology which are important for "general medicine". Written and practical exams take place at the end of the block. Although there is more required attendance and increased demands on students' time, dermatology has received very positive evaluation results. Students consider their gain in knowledge and skills as very high. The new curriculum in Hamburg could provide helpful orientation for other medical faculties in changing their curricula for the subject "dermatology and venereology" according to the new educational law.


Subject(s)
Curriculum/standards , Dermatology/education , Dermatology/legislation & jurisprudence , Schools, Medical/legislation & jurisprudence , Schools, Medical/standards , Venereology/education , Venereology/legislation & jurisprudence , Dermatology/standards , Germany , Guidelines as Topic , Venereology/standards
6.
Ann Allergy Asthma Immunol ; 95(6): 593-9, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16400901

ABSTRACT

BACKGROUND: Polyoxyethylene-sorbitan-20-monooleate (also known as polysorbate 80 and Tween 80) is a solubilizing agent ubiquitously used in nutritives, creams, ointments, lotions, and multiple medical preparations (e.g., vitamin oils, vaccines, and anticancer agents) and as an additive in tablets. Whereas its relevance as a contact allergen has declined during the past decades, it is of current relevance as a "hidden" inductor of anaphylactoid reactions. OBJECTIVE: To identify polysorbate 80 (generally believed to be an inert vehicle) as an inductor of a severe anaphylactoid reaction. METHODS: Skin prick testing, enzyme-linked immunosorbent assay, IgE immunoblotting, and flow cytometric detection of basophil activation were performed in controls and in a patient with a medical history of anaphylactic shock due to intravenous administration of a multivitamin product during pregnancy. RESULTS: Polysorbate 80 was identified as the causative agent for the anaphylactoid reaction of nonimmunologic origin in the patient. Polysorbate specific IgE antibodies were not identified in enzyme-linked immunosorbent assay and immunoblot examinations, confirming the nonimmunologic nature of the anaphylactoid reaction. CONCLUSIONS: Polysorbate 80 is a ubiquitously used solubilizing agent that can cause severe nonimmunologic anaphylactoid reactions.


Subject(s)
Anaphylaxis/chemically induced , Polysorbates/adverse effects , Surface-Active Agents/adverse effects , Vitamins/adverse effects , Vitamins/chemistry , Anaphylaxis/immunology , Basophils/immunology , Drug-Related Side Effects and Adverse Reactions , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , Humans , Immunoblotting , Immunoglobulin E/blood , Pharmaceutical Preparations/chemistry , Polysorbates/chemistry , Pregnancy , Skin Tests , Surface-Active Agents/chemistry , Vitamins/administration & dosage
7.
J Am Acad Dermatol ; 50(3): 363-7, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14988676

ABSTRACT

Photodynamic therapy after topical application of 5-aminolevulinic acid is an effective therapy for nonmelanoma epithelial skin cancers. It has also been used for some cases of cutaneous T-cell lymphoma. We treated 4 patients with different cutaneous T-cell lymphomas with photodynamic therapy. Those patients had previously reached a partial remission with more conventional therapies, but single lesions had remained. In all of these cases a complete remission of these lesions was achieved. We, therefore, suggest that photodynamic therapy can be a useful additional treatment modality for patients with therapy-resistant lesions of cutaneous T-cell lymphoma.


Subject(s)
Aminolevulinic Acid/administration & dosage , Lymphoma, T-Cell/drug therapy , Photochemotherapy , Skin Neoplasms/drug therapy , Administration, Topical , Adult , Aged , Drug Resistance, Neoplasm , Female , Humans , Male , Middle Aged
8.
J Am Acad Dermatol ; 46(4): 531-5, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11907502

ABSTRACT

Small to medium-sized pleomorphic cutaneous T-cell lymphomas represent a provisional entity in the new European Organization for Research and Treatment of Cancer classification. We describe 3 patients with a localized and outstanding stable variant of this tumor. A median follow-up period of 50 months did not reveal any spread into regional lymph nodes or to distant sites in any patient.


Subject(s)
Lymphoma, Non-Hodgkin/pathology , Lymphoma, T-Cell, Cutaneous/pathology , Skin Neoplasms/pathology , Adult , Diagnosis, Differential , Female , Humans , Lymphoma, Non-Hodgkin/diagnosis , Lymphoma, T-Cell, Cutaneous/diagnosis , Male , Middle Aged , Skin Neoplasms/diagnosis
9.
J Am Acad Dermatol ; 46(2 Suppl Case Reports): S14-5, 2002 Feb.
Article in English | MEDLINE | ID: mdl-11807459

ABSTRACT

Temporal arteritis is a giant cell arteritis that affects large- or medium-sized elastic arteries. Often, only 1 temporal artery is affected. We describe a patient with both temporal arteries being involved simultaneously. To our knowledge, this particular constellation has rarely been described so far.


Subject(s)
Erythema/etiology , Giant Cell Arteritis/complications , Aged , Anti-Inflammatory Agents/therapeutic use , Erythema/drug therapy , Female , Giant Cell Arteritis/pathology , Humans , Methylprednisolone/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...